Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Mechanisms of targeted therapy resistance take a de-TOR.

Literature DB >> 24029226

Mechanisms of targeted therapy resistance take a de-TOR.

Leanna R Gentry¹, Timothy D Martin, Channing J Der.

Abstract

The effectiveness of cancer therapeutics targeting signal transduction pathways is comprised of a diversity of mechanisms that drive de novo or acquired resistance. Two recent studies identify mTOR activation as a point of convergence of mechanisms that cause resistance to inhibitors of the Raf-MEK-ERK and PI3K signaling.

Entities: Chemical Disease Gene Mutation Species

Mesh：

Substances：

Year: 2013 PMID： 24029226 PMCID： PMC3810955 DOI： 10.1016/j.ccr.2013.08.021

Source DB: PubMed Journal: Cancer Cell ISSN： 1535-6108 Impact factor: 31.743

10 in total

1. Improved survival with MEK inhibition in BRAF-mutated melanoma.

Authors: Keith T Flaherty; Caroline Robert; Peter Hersey; Paul Nathan; Claus Garbe; Mohammed Milhem; Lev V Demidov; Jessica C Hassel; Piotr Rutkowski; Peter Mohr; Reinhard Dummer; Uwe Trefzer; James M G Larkin; Jochen Utikal; Brigitte Dreno; Marta Nyakas; Mark R Middleton; Jürgen C Becker; Michelle Casey; Laurie J Sherman; Frank S Wu; Daniele Ouellet; Anne-Marie Martin; Kiran Patel; Dirk Schadendorf
Journal: N Engl J Med Date: 2012-06-04 Impact factor: 91.245

2. Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

Authors: Paul B Chapman; Axel Hauschild; Caroline Robert; John B Haanen; Paolo Ascierto; James Larkin; Reinhard Dummer; Claus Garbe; Alessandro Testori; Michele Maio; David Hogg; Paul Lorigan; Celeste Lebbe; Thomas Jouary; Dirk Schadendorf; Antoni Ribas; Steven J O'Day; Jeffrey A Sosman; John M Kirkwood; Alexander M M Eggermont; Brigitte Dreno; Keith Nolop; Jiang Li; Betty Nelson; Jeannie Hou; Richard J Lee; Keith T Flaherty; Grant A McArthur
Journal: N Engl J Med Date: 2011-06-05 Impact factor: 91.245

3. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.

Authors: Johanna C Bendell; Jordi Rodon; Howard A Burris; Maja de Jonge; Jaap Verweij; Diana Birle; David Demanse; Stefan S De Buck; Qinhua C Ru; Malte Peters; Michael Goldbrunner; José Baselga
Journal: J Clin Oncol Date: 2011-12-12 Impact factor: 44.544

Review 4. Resistance to BRAF-targeted therapy in melanoma.

Authors: Ryan J Sullivan; Keith T Flaherty
Journal: Eur J Cancer Date: 2013-01-02 Impact factor: 9.162

5. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.

Authors: Axel Hauschild; Jean-Jacques Grob; Lev V Demidov; Thomas Jouary; Ralf Gutzmer; Michael Millward; Piotr Rutkowski; Christian U Blank; Wilson H Miller; Eckhart Kaempgen; Salvador Martín-Algarra; Boguslawa Karaszewska; Cornelia Mauch; Vanna Chiarion-Sileni; Anne-Marie Martin; Suzanne Swann; Patricia Haney; Beloo Mirakhur; Mary E Guckert; Vicki Goodman; Paul B Chapman
Journal: Lancet Date: 2012-06-25 Impact factor: 79.321

6. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.

Authors: Sauveur-Michel Maira; Sabina Pecchi; Alan Huang; Matthew Burger; Mark Knapp; Dario Sterker; Christian Schnell; Daniel Guthy; Tobi Nagel; Marion Wiesmann; Saskia Brachmann; Christine Fritsch; Marion Dorsch; Patrick Chène; Kevin Shoemaker; Alain De Pover; Daniel Menezes; Georg Martiny-Baron; Doriano Fabbro; Christopher J Wilson; Robert Schlegel; Francesco Hofmann; Carlos García-Echeverría; William R Sellers; Charles F Voliva
Journal: Mol Cancer Ther Date: 2011-12-21 Impact factor: 6.261

7. mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer.

Authors: Moshe Elkabets; Sadhna Vora; Dejan Juric; Natasha Morse; Mari Mino-Kenudson; Taru Muranen; Jessica Tao; Ana Bosch Campos; Jordi Rodon; Yasir H Ibrahim; Violeta Serra; Vanessa Rodrik-Outmezguine; Saswati Hazra; Sharat Singh; Phillip Kim; Cornelia Quadt; Manway Liu; Alan Huang; Neal Rosen; Jeffrey A Engelman; Maurizio Scaltriti; José Baselga
Journal: Sci Transl Med Date: 2013-07-31 Impact factor: 17.956

8. TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma.

Authors: Ryan B Corcoran; Stephen Michael Rothenberg; Aaron N Hata; Anthony C Faber; Adriano Piris; Rosalynn M Nazarian; Ronald D Brown; Jason T Godfrey; Daniel Winokur; John Walsh; Mari Mino-Kenudson; Shyamala Maheswaran; Jeffrey Settleman; Jennifer A Wargo; Keith T Flaherty; Daniel A Haber; Jeffrey A Engelman
Journal: Sci Transl Med Date: 2013-07-31 Impact factor: 17.956

Review 9. BRAF in melanoma: current strategies and future directions.

Authors: April K S Salama; Keith T Flaherty
Journal: Clin Cancer Res Date: 2013-06-14 Impact factor: 12.531

10. Mutations of the BRAF gene in human cancer.

Authors: Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal: Nature Date: 2002-06-09 Impact factor: 49.962